Read more
5:45 PM ยท 9 January 2025

Sanofi reports a phase 3 trial success ๐Ÿ”Ž Promising year ahead?

-
-
Open account Download free app
Sanofi’s blood cancer treatment has achieved key co-primary endpoints in the phase 3 Iraklia study. The stock gained 1% today in Paris, continuing its newly found upward...

Log in or create a free account to keep reading

Analyses by award-winning experts

Create account  Log in

Join over 2 000 000 XTB Group Clients from around the world

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissรฃo de Valores Mobiliรกrios (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits